Zenith Capital (Zenith Capital) Debt-to-Revenue : 0.00 (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Zenith Capital's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Zenith Capital's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Zenith Capital's annualized Revenue for the quarter that ended in . 20 was $0.00 Mil.

Zenith Capital Debt-to-Revenue Historical Data

The historical data trend for Zenith Capital's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Debt-to-Revenue Chart

Zenith Capital Annual Data

Trend

Debt-to-Revenue

Zenith Capital Quarterly Data

Debt-to-Revenue

Competitive Comparison of Zenith Capital's Debt-to-Revenue

For the Biotechnology subindustry, Zenith Capital's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Debt-to-Revenue falls into.

Zenith Capital Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Zenith Capital's Debt-to-Revenue for the fiscal year that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	N/A
	=	N/A

Zenith Capital's annualized Debt-to-Revenue for the quarter that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (. 20) Revenue data.

Zenith Capital Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines